EUVIMEDEUVIMED entdecken
Crossref

Interleukin‐35 protein inhibits osteoclastogenesis and attenuates collagen‐induced arthritis in mice

Lin Yuan, Yuxuan Li, Dan Liu, Hui Zhang, Jie Yang, Hui Shen, Liping Xia, Lutian Yao, Jing Lu iD

Journal of Cellular Physiology · 2024

DOI: 10.1002/jcp.31231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2024. Verfasst von Lin Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management, The First Affiliated Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Arthritis, Experimental, Interleukins, Osteogenesis, Osteoclasts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, China Postdoctoral Science Foundation, 345 Talent Project of Shengjing Hospital of China Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a chronic autoimmune disease. Its pathological features include synovial inflammation, bone erosion, and joint structural damage. Our previous studies have shown that interleukin (IL)‐35 is involved in the pathogenesis of bone loss in RA patients. In this study, we are further evaluating the efficacy of IL‐35 on collagen‐induced arthritis (CIA) in the mouse model. Male DBA/1J mice ( n = 10) were initially immunized, 2 μg/mouse IL‐35 was injected intraperitoneally every week for 3 weeks after the establishment of the CIA model. Clinical arthritis, histopathological analysis, and three‐dimensional micro‑computed tomography (3D micro‑CT) were determined after the mice were anesthetized on the 42th day. In vitro, RANKL/M‐CSF induced mouse preosteoclasts (RAW264.7 cells line) was subjected to antiarthritis mechanism study in the presence of IL‐35. The results of clinical arthritis, histopathological analysis, and 3D micro‑CT, the expression of RANK/RANKL/OPG axis, inflammatory cytokines, and osteoclastogenesis‐related makers demonstrated decreasing severity of synovitis and bone destruction in the ankle joints after IL‐35 treatment. Furthermore, IL‐35 attenuated inflammatory cytokine production and the expression of osteoclastogenesis‐related makers in a mouse preosteoclasts cell line RAW264.7. The osteoclastogenesis‐related makers were significantly reduced in IL‐35 treated RAW264.7 cells line after blockage with the JAK/STAT1 signaling pathway. These results demonstrated that IL‐35 protein could inhibits osteoclastogenesis and attenuates CIA in mice. We concluded that IL‐35 can exhibit anti‐osteoclastogenesis effects by reducing the expression of inflammatory cytokines and osteoclastogenesis‐related makers, thus alleviating bone destruction in the ankle joint and could be a potential therapeutic target for RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, ExperimentalInterleukinsOsteogenesisOsteoclastsMice, Inbred DBARANK LigandAnimalsMiceMaleRAW 264.7 CellsArthritis, RheumatoidSignal TransductionX-Ray MicrotomographyReceptor Activator of Nuclear Factor-kappa BCytokines

Stichwörter der Autor:innen

bone destructioninterleukin‐35osteoclastsrheumatoid arthritissignaling pathway

Substanzen

Interleukinsinterleukin-35, mouseRANK LigandReceptor Activator of Nuclear Factor-kappa BCytokines

Autor:innen und Institutionen

  • Department of Health Management, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, China.
  • Department of Critical Care Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Rheumatology and Immunology, The Fifth People Hospital, Shenyang, China.
  • Department of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Department of Orthopedic, The First Affiliated Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Jing Lu

Förderung

  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • 345 Talent Project of Shengjing Hospital of China Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Yuan, L., Li, Y., Liu, D., Zhang, H., Yang, J., Shen, H., Xia, L., Yao, L., & Lu, J. (2024). Interleukin‐35 protein inhibits osteoclastogenesis and attenuates collagen‐induced arthritis in mice. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31231

Vancouver

Yuan L, Li Y, Liu D, Zhang H, Yang J, Shen H, et al. Interleukin‐35 protein inhibits osteoclastogenesis and attenuates collagen‐induced arthritis in mice. Journal of Cellular Physiology. 2024. doi:10.1002/jcp.31231

BibTeX
@article{Yuan2024,
  author = {Yuan, Lin and Li, Yuxuan and Liu, Dan and Zhang, Hui and Yang, Jie and Shen, Hui and Xia, Liping and Yao, Lutian and Lu, Jing},
  title = {Interleukin‐35 protein inhibits osteoclastogenesis and attenuates collagen‐induced arthritis in mice},
  journal = {Journal of Cellular Physiology},
  year = {2024},
  doi = {10.1002/jcp.31231}
}
Kostenlos starten →